
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Nurix Therapeutics Inc (NRIX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NRIX (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $29.83
1 Year Target Price $29.83
10 | Strong Buy |
6 | Buy |
2 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.14% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 807.31M USD | Price to earnings Ratio - | 1Y Target Price 29.83 |
Price to earnings Ratio - | 1Y Target Price 29.83 | ||
Volume (30-day avg) 18 | Beta 2.15 | 52 Weeks Range 8.18 - 29.56 | Updated Date 08/15/2025 |
52 Weeks Range 8.18 - 29.56 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.6 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -234.57% | Operating Margin (TTM) -109.68% |
Management Effectiveness
Return on Assets (TTM) -26.13% | Return on Equity (TTM) -50.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 373455188 | Price to Sales(TTM) 9.13 |
Enterprise Value 373455188 | Price to Sales(TTM) 9.13 | ||
Enterprise Value to Revenue 4.23 | Enterprise Value to EBITDA -3.35 | Shares Outstanding 76449400 | Shares Floating 57946318 |
Shares Outstanding 76449400 | Shares Floating 57946318 | ||
Percent Insiders 1.43 | Percent Institutions 110.98 |
Upturn AI SWOT
Nurix Therapeutics Inc

Company Overview
History and Background
Nurix Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule therapies designed to modulate cellular protein levels to treat cancer and other diseases. Founded in 2009, the company has progressed through various stages of research and development, advancing multiple programs into clinical trials.
Core Business Areas
- Drug Discovery & Development: Nurix focuses on identifying and developing small molecule therapies that target E3 ligases to modulate protein levels, thereby treating diseases like cancer and immune disorders.
Leadership and Structure
The leadership team includes individuals with extensive experience in drug discovery, development, and commercialization. The organizational structure is typical of a biotechnology company, with research, development, and administrative functions.
Top Products and Market Share
Key Offerings
- NX-2127: NX-2127 is a potent, oral BTK degrader in Phase 1 clinical trials for B-cell malignancies. Market share is currently 0 as it is pre-revenue. Competitors include BTK inhibitors such as Ibrutinib (Imbruvica), Acalabrutinib (Calquence), and Zanubrutinib (Brukinsa). There are other degrader drugs in clinical trials.
- NX-1607: NX-1607 is a CBL-B inhibitor targeting tumor microenvironment. Market share is currently 0 as it is pre-revenue. Competitors are other investigational drugs targeting the tumor microenvironment.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically in the oncology and immunology sectors, is highly competitive and rapidly evolving. There's a growing focus on targeted therapies and personalized medicine.
Positioning
Nurix is positioned as an innovative company utilizing targeted protein modulation to address unmet needs in cancer and immunology. Their competitive advantage lies in their unique platform targeting E3 ligases.
Total Addressable Market (TAM)
The total addressable market for cancer and immunology therapeutics is substantial, estimated to be hundreds of billions of dollars. Nurix's position depends on the clinical success and commercialization of its pipeline.
Upturn SWOT Analysis
Strengths
- Novel drug discovery platform
- Strong intellectual property portfolio
- Experienced management team
- Focus on high unmet medical needs
Weaknesses
- Dependence on successful clinical trials
- High cash burn rate
- Limited commercialization experience
- Reliance on funding
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new targets
- Positive clinical trial results
- Acquisition or licensing of complementary technologies
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Patent challenges
- Economic downturn affecting investment in biotech
Competitors and Market Share
Key Competitors
- BMY
- MRK
- ABBV
- PFE
Competitive Landscape
Nurix faces significant competition from larger pharmaceutical companies with established oncology and immunology portfolios. Nurixu2019s novel approach using E3 ligases provides a potential differentiating factor, but it must demonstrate clinical efficacy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by pipeline advancement rather than revenue generation.
Future Projections: Future growth depends on clinical trial outcomes and potential partnerships. Analyst estimates are not readily available for direct structured output.
Recent Initiatives: Recent initiatives include advancing NX-2127 and NX-1607 through clinical trials and exploring new E3 ligase targets.
Summary
Nurix Therapeutics is a development-stage biopharmaceutical company pioneering targeted protein modulation. Their innovative platform offers potential, but they face challenges including dependence on clinical trial success and significant competition. Positive clinical data and strategic partnerships are crucial for their long-term growth and success. The company needs to focus on securing financing to ensure continued operation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Nurix Therapeutics Investor Relations
- SEC Filings
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company-specific events can significantly impact the company's performance. The AI rating is an estimate and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nurix Therapeutics Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2020-07-24 | CEO, President & Director Dr. Arthur T. Sands M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 286 | Website https://www.nurixtx.com |
Full time employees 286 | Website https://www.nurixtx.com |
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.